Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
- Bobrowicz M Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
- Fassnacht C Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
- Ignatova D Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
- Chang YT Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
- Dimitriou F Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
- Guenova E Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, emmanuella.guenova@unil.ch.
- 2020-07-22
Published in:
- International archives of allergy and immunology. - 2020
English
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous disease group of unknown etiology with a complex immunological background. As CTCL arises from T cells that have a vital role in the antitumor response, their therapy is largely aimed at reversing the immunological mechanisms leading to or manifesting during this malignancy. Early disease stages can be controlled with skin-directed therapy in most CTCL cases. Still, advanced CTCL has a dismal prognosis and warrants systemic therapy. Despite considerable progress in understanding the pathophysiology of the disease and the numerous systemic treatment options available, long-term remission rates with conventional treatments alone are still low. Allogeneic hematopoietic stem cell transplantation is currently the only curative option for advanced CTCL, including mycosis fungoides and Sézary syndrome. The aims of this review is to summarize the recent findings on the immunology of this heterogeneous disease and to present the advances in its clinical management.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1159/000509281
- PMID 32690848
- Persistent URL
- https://sonar.ch/global/documents/226201
Statistics
Document views: 26
File downloads:
- fulltext.pdf: 0